Information Provided By:
Fly News Breaks for November 2, 2015
RLYP, ZSPH
Nov 2, 2015 | 13:45 EDT
After hosting a call with a physician who previously served the FDA, Morgan Stanley analyst Andrew Berens said he believes it "highly unlikely" that ZS Pharma's (ZSPH) ZS-9 will receive a black box warning like competitor Relypsa's (RLYP) Veltassa did. That view assume ZS' in-vitro studies were conducted appropriately, Berens noted. The analyst keeps an Overweight rating and $76 price target on ZS Pharma shares.
News For ZSPH;RLYP From the Last 2 Days
There are no results for your query ZSPH;RLYP